Cancer News and Research

Latest Cancer News and Research

Websites bridge gaps between patients and doctors and marketers

Conveying how well a therapy works and doing so in understandable terms isn't easy, but a group of physicians is trying to change that The Wall Street Journal's Health Blog reports.

8 Oct 2010

Prostate cancer updates

Scientists have found that genetic variations for an enzyme involved in cell energy metabolism may increase the risk of prostate cancer. This variation in genes may impair the enzyme phosphodiesterase 11A (PDE11A), which helps regulate cells' responses to hormones and other signals, according to the U.S. National Institute of Child Health and Human Development researchers and colleagues.

8 Oct 2010

Hospitals improve patient care by reducing blood transfusions: Study

A Loyola University Hospital study has demonstrated how the hospital has improved patient safety and cut costs by reducing the number of blood transfusions.

7 Oct 2010

AMIC signs world-wide license for brachytherapy seed with fast-dissolving matrix

Advanced Medical Isotope Corporation, a company engaged in the production and distribution of medical isotopes, is delighted to announce the execution of an exclusive world-wide license for patented technology for a proprietary brachytherapy seed with a fast-dissolving matrix for optimized delivery of radionuclides to cancer tissue.

7 Oct 2010

Onyx Pharmaceuticals announces delay in NDA filing for carfilzomib

Onyx Pharmaceuticals, Inc. today announced that it will delay its New Drug Application (NDA) filing for carfilzomib based on a recent meeting with the Chemistry, Manufacturing and Controls (CMC) review division of the U.S. Food and Drug Administration (FDA).

7 Oct 2010

Cyclacel announces completion of private placement sale

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced today that it consummated its previously announced private placement to sell approximately $15.2 million of its units to several institutional investors, including the Special Situations Funds, for net proceeds of approximately $14.1 million after the deduction of offering expenses.

7 Oct 2010

Cepheid collaborates with Novartis to commercialize BCR-ABL monitoring test

Cepheid today announced an exclusive collaboration with Novartis for the commercialization of a test for monitoring the BCR-ABL gene transcript in peripheral blood specimens from patients diagnosed with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). Together with other lab tests, monitoring levels of BCR-ABL transcripts in Ph+ CML patients will aid in patient management.

7 Oct 2010

Bayer HealthCare, Onyx to present data on Nexavar tablets at ESMO Congress

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that more than 20 studies evaluating the use of Nexavar® (sorafenib) tablets will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, October 8-12, 2010 in Milan, Italy.

7 Oct 2010

AngioDynamics reports 3% increase in net sales for fiscal 2011 first quarter

AngioDynamics, a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease, today reported financial results for the fiscal 2011 first quarter ended August 31, 2010 that were in line with the preliminary results reported on September 7, 2010.

7 Oct 2010

Cs-131 brachytherapy seed implant can treat metastasized cancer

IsoRay, Inc. announced today another milestone in the use of Cesium-131 (Cs-131) brachytherapy seeds (internal radiation therapy). Doctors at a world renowned medical facility have performed the world's first Cs-131 brachytherapy seed implant following a wedge resection of a lung tumor which originated from a form of malignant uterine cancer. Initially used to treat primary cancers, Cs-131 seeds are now being used to treat metastasized cancer.

7 Oct 2010

AnalizaDx SIA technology, Nanosphere Verisens assay effective for prostate cancer diagnosis

At the annual meeting of the North-Central American Urological Association, Mark Stovsky, MD, Case Western Reserve University School of Medicine Case Medical Center, and principal investigator, presented positive data combining the AnalizaDx SIA technology with the Nanosphere Verisens ultra-sensitive PSA assay.

7 Oct 2010

Study shows radioembolisation with TheraSphere effective for primary liver cancer

MDS Nordion, a leading provider of products and services to the global health science market, today announced that the first large European study using Yttrium-90 (Y-90) glass microspheres has been published on the use of TheraSphere, an innovative radioembolisation therapy for the localised treatment of patients with advanced hepatocellular carcinoma (HCC) or primary liver cancer.

7 Oct 2010

Vical to manufacture pDNA vaccines against HIV

Vical Incorporated today announced that the company has agreed to manufacture plasmid DNA (pDNA) vaccines against HIV under a $2.4 million contract with the IPPOX Foundation, a collaborating institution for the Poxvirus Vaccine Regimen Design (PVRD) led by the Centre Hospitalier Universitaire Vaudois (CHUV) under the auspices of the Collaboration for AIDS Vaccine Discovery (CAVD).

7 Oct 2010

Should Medicare consider cost-effectiveness when setting reimbursement rates?

Medicare reimbursement rates should be based on how cost effective the treatment is for a particular illness, according to a piece by two policy experts in the October edition of Health Affairs.

7 Oct 2010

Researchers shed new light about long non-coding RNA molecules

Despite progress in decoding the genome, scientists estimate that fully 95 percent of our DNA represents dark, unknown territory. In the October 1 issue of the journal Cell researchers at The Wistar Institute shed new light on the genetic unknown with the discovery of the ability of long non-coding RNA (ncRNA) to promote gene expression.

7 Oct 2010

Myrexis to present MPI-0485520 preclinical data at Annual Scientific Meeting

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present a poster at the 74th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP), to be held November 7-11, 2010 in Atlanta, Georgia.

7 Oct 2010

Simple tips to prevent breast cancer

Breast cancer is one of the most common cancers affecting American women and may lead to more than 38,000 deaths this year. Medical Doctor, Researcher and Cancer expert, Dr. Isaac Eliaz shares 8 simple tips during Breast Cancer Awareness Month, so you can learn more about treating and preventing breast cancer.

7 Oct 2010

SMI completes development of SkinSpect for early detection of melanoma

Cascade Technologies Corp. announced today that its wholly-owned subsidiary, Spectral Molecular Imaging, Inc. (SMI), completed, under a previously introduced accelerated timeline, the development of its initial product SkinSpect, aimed at early detection of melanoma by the company's proprietary form of hyperspectral imaging.

7 Oct 2010

Role of TGF-ß in cancer diseases

During this year's BIOTECHNICA exhibition, the international biotech news magazine „GEN - Genetic Engineering & Biotechnology News yesterday on 5 October 2010, held an information event with subsequent panel discussion featuring the topic TGF-ß an important target in cancer diseases.

7 Oct 2010

Majority of cancer patients are concerned about treatment costs: MDLinx

Ninety five percent of the nation's oncologists report a rise in their patients' concerns over treatment costs in the past six months, according to a survey conducted by MDLinx, one of the U.S.'s largest doctor portals.

7 Oct 2010